Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIGILANT: depemokimab early maintenance treatment in COPD with type 2 inflammation
CTR20254208Phase 3Active
- Sponsor
- GSK
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Depemokimab with Placebo (2 arms). Primary endpoint: Annualized rate of moderate/severe COPD exacerbations. Started Feb 2026; status: active.
02
Drugs
depemokimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20254208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254208.